Drug news
NICE recommends use of Brilique (ticagrelor) at reduced dose of 60 mg to reduce risk of heart attack.- AstraZeneca
The National Institute for Care and Health Excellence has recommended the use of Brilique (ticagrelor) from AstraZeneca at a lower 60 mg dose, twice daily, and in combination with aspirin in patients who have had a myocardial infarction and have completed an initial 12 months of treatment at the higher dose of 90 mg (plus aspirin).The aim is to reduce the risk of a heart attack.The draft guidance does not recommend the use of ticagrelor beyond three years due to limited safety and efficacy data.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.